Health · Medical Research · 1 day ago
CG Oncology bladder treatment cut tumor recurrence risk by 68% in trial
CG Oncology reported positive Phase 3 results for its bladder cancer treatment, cretostimogene.
The randomized trial enrolled 367 patients with intermediate-risk bladder cancer, a localized form of the disease.
The treatment reduced recurrence risk by 68% compared with current medical practice.
Cretostimogene is made from an engineered common cold virus and is delivered directly into the bladder through a catheter.
Patients are usually monitored every three months after their tumors are removed with minimally invasive surgery, and recurrence can mean more procedures over time.
The results may change how doctors treat some patients with bladder cancer, but no further next steps were stated.
CG Oncology said its bladder cancer immunotherapy reduced the risk of tumor recurrence by 68% compared with current medical practice.
The positive results came from a randomized Phase 3 study of patients with intermediate-risk bladder cancer.
The treatment, cretostimogene, is infused directly into the bladder through a catheter.
The study enrolled 367 patients.
The results may change how physicians treat certain patients with bladder cancer.
- Who
- CG Oncology reported the results.
- What
- Its treatment cretostimogene reduced the risk of tumor recurrence by 68% compared with current medical practice.
- When
- The positive results were announced Monday, Nov. 16, 2026.
- Where
- Not stated.
- Why
- The Phase 3 study tested whether the treatment could reduce tumor recurrence in patients with intermediate-risk bladder cancer.
This story does not have two clearly opposing sides.
The randomized Phase 3 study enrolled 367 patients with intermediate-risk bladder cancer.
CG Oncology announced positive study results showing a 68% reduction in the risk of tumor recurrence compared with current medical practice.
- Treatment
- Cretostimogene
- Recurrence risk reduction
- 68% compared with current medical practice
- Trial phase
- Phase 3
- Trial participants
- 367 patients with intermediate-risk bladder cancer
- Delivery method
- Infused directly into the bladder through a catheter